94 related articles for article (PubMed ID: 22705392)
21. Effect of the adenosine A2A receptor antagonist MSX-3 on motivational disruptions of maternal behavior induced by dopamine antagonism in the early postpartum rat.
Pereira M; Farrar AM; Hockemeyer J; Müller CE; Salamone JD; Morrell JI
Psychopharmacology (Berl); 2011 Jan; 213(1):69-79. PubMed ID: 20848086
[TBL] [Abstract][Full Text] [Related]
22. Preladenant, a novel adenosine A(2A) receptor antagonist for the potential treatment of parkinsonism and other disorders.
Salamone JD
IDrugs; 2010 Oct; 13(10):723-31. PubMed ID: 20878595
[TBL] [Abstract][Full Text] [Related]
23. Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism.
Salamone JD; Betz AJ; Ishiwari K; Felsted J; Madson L; Mirante B; Clark K; Font L; Korbey S; Sager TN; Hockemeyer J; Muller CE
Front Biosci; 2008 May; 13():3594-605. PubMed ID: 18508458
[TBL] [Abstract][Full Text] [Related]
24. Bupropion increases selection of high effort activity in rats tested on a progressive ratio/chow feeding choice procedure: implications for treatment of effort-related motivational symptoms.
Randall PA; Lee CA; Podurgiel SJ; Hart E; Yohn SE; Jones M; Rowland M; López-Cruz L; Correa M; Salamone JD
Int J Neuropsychopharmacol; 2014 Oct; 18(2):. PubMed ID: 25575584
[TBL] [Abstract][Full Text] [Related]
25. Adenosine receptor-mediated modulation of dopamine release in the nucleus accumbens depends on glutamate neurotransmission and N-methyl-D-aspartate receptor stimulation.
Quarta D; Borycz J; Solinas M; Patkar K; Hockemeyer J; Ciruela F; Lluis C; Franco R; Woods AS; Goldberg SR; Ferré S
J Neurochem; 2004 Nov; 91(4):873-80. PubMed ID: 15525341
[TBL] [Abstract][Full Text] [Related]
26. Involvement of adenosine A2A and dopamine receptors in the locomotor and sensitizing effects of cocaine.
Filip M; Frankowska M; Zaniewska M; Przegaliński E; Muller CE; Agnati L; Franco R; Roberts DC; Fuxe K
Brain Res; 2006 Mar; 1077(1):67-80. PubMed ID: 16516871
[TBL] [Abstract][Full Text] [Related]
27. Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice.
Marcellino D; Lindqvist E; Schneider M; Müller CE; Fuxe K; Olson L; Galter D
Neurobiol Dis; 2010 Nov; 40(2):460-6. PubMed ID: 20656029
[TBL] [Abstract][Full Text] [Related]
28. The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio/chow feeding choice task: reversal with antidepressant drugs.
Randall PA; Lee CA; Nunes EJ; Yohn SE; Nowak V; Khan B; Shah P; Pandit S; Vemuri VK; Makriyannis A; Baqi Y; Müller CE; Correa M; Salamone JD
PLoS One; 2014; 9(6):e99320. PubMed ID: 24937131
[TBL] [Abstract][Full Text] [Related]
29. Induction of oral tremor in mice by the acetylcholinesterase inhibitor galantamine: Reversal with adenosine A2A antagonism.
Podurgiel SJ; Spencer T; Kovner R; Baqi Y; Müller CE; Correa M; Salamone JD
Pharmacol Biochem Behav; 2016 Jan; 140():62-7. PubMed ID: 26459156
[TBL] [Abstract][Full Text] [Related]
30. The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism.
Correa M; Wisniecki A; Betz A; Dobson DR; O'Neill MF; O'Neill MJ; Salamone JD
Behav Brain Res; 2004 Jan; 148(1-2):47-54. PubMed ID: 14684247
[TBL] [Abstract][Full Text] [Related]
31. Stimulant effects of adenosine antagonists on operant behavior: differential actions of selective A2A and A1 antagonists.
Randall PA; Nunes EJ; Janniere SL; Stopper CM; Farrar AM; Sager TN; Baqi Y; Hockemeyer J; Müller CE; Salamone JD
Psychopharmacology (Berl); 2011 Jul; 216(2):173-86. PubMed ID: 21347642
[TBL] [Abstract][Full Text] [Related]
32. Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.
Sams AG; Mikkelsen GK; Larsen M; Langgård M; Howells ME; Schrøder TJ; Brennum LT; Torup L; Jørgensen EB; Bundgaard C; Kreilgård M; Bang-Andersen B
J Med Chem; 2011 Feb; 54(3):751-64. PubMed ID: 21210664
[TBL] [Abstract][Full Text] [Related]
33. Locomotor activation by theacrine, a purine alkaloid structurally similar to caffeine: involvement of adenosine and dopamine receptors.
Feduccia AA; Wang Y; Simms JA; Yi HY; Li R; Bjeldanes L; Ye C; Bartlett SE
Pharmacol Biochem Behav; 2012 Aug; 102(2):241-8. PubMed ID: 22579816
[TBL] [Abstract][Full Text] [Related]
34. Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal.
Broderick PA; Hope O; Okonji C; Rahni DN; Zhou Y
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):157-71. PubMed ID: 14687870
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition.
Mihara T; Mihara K; Yarimizu J; Mitani Y; Matsuda R; Yamamoto H; Aoki S; Akahane A; Iwashita A; Matsuoka N
J Pharmacol Exp Ther; 2007 Nov; 323(2):708-19. PubMed ID: 17684118
[TBL] [Abstract][Full Text] [Related]
36. Differential effects of adenosine antagonists in two models of parkinsonian tremor.
Trevitt J; Kawa K; Jalali A; Larsen C
Pharmacol Biochem Behav; 2009 Nov; 94(1):24-9. PubMed ID: 19602422
[TBL] [Abstract][Full Text] [Related]
37. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
Hu XT; White FJ
Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and properties of a new water-soluble prodrug of the adenosine A 2A receptor antagonist MSX-2.
Vollmann K; Qurishi R; Hockemeyer J; Müller CE
Molecules; 2008 Feb; 13(2):348-59. PubMed ID: 18305423
[TBL] [Abstract][Full Text] [Related]
39. The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task: reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion.
Yohn SE; Thompson C; Randall PA; Lee CA; Müller CE; Baqi Y; Correa M; Salamone JD
Psychopharmacology (Berl); 2015 Apr; 232(7):1313-23. PubMed ID: 25323625
[TBL] [Abstract][Full Text] [Related]
40. Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis.
Marcellino D; Carriba P; Filip M; Borgkvist A; Frankowska M; Bellido I; Tanganelli S; Müller CE; Fisone G; Lluis C; Agnati LF; Franco R; Fuxe K
Neuropharmacology; 2008 Apr; 54(5):815-23. PubMed ID: 18262573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
